ATS Books a Record Backlog and Guides Down Anyway

Record life-sciences orders, a Canadian tariff shock arriving a year late, and a CEO who has now withdrawn the 'modest growth' promise twice reaffirmed

ATS · Earnings Call · 2026-11-04

The paradox: best order book ever, worst margin in a while

ATS Corporation came into its fiscal Q2 2027 call with an odd story to tell. Order bookings were $827 million, up 12.7% year over year, with a trailing-twelve-month book-to-bill of 1.05:1 and roughly $2 billion of backlog — including $1.2 billion in life sciences, the highest in company history. And yet revenue fell 8.6% to $666 million, adjusted earnings from operations dropped 27.4% to $57.4 million, and the adjusted operating margin compressed to 8.6% from 10.9%. Gross margin gave up 131 basis points to 28.6%. That gap between orders and income is the whole call in one line. The bookings are real; the revenue they represent is slow. Three separate analysts — Maxim Sytchev, Michael Glen, and Fred Tremblay — spent their time probing the same wound: how long does the backlog take to become revenue? Management conceded it is a while. “it will take another quarter or 2 before it starts to really start to reenergize the revenue growth” — Douglas William Wright, Chief Executive Officer · 2026-11-04, Douglas Wright said. The keyword set has already named the problem: longer dated projects and lead time both spiked into the company's top-3 themes this quarter, having barely registered before. When your language of growth becomes a language of duration, the market notices.

Section 38: a tariff story arriving a year late

Here is the genuinely company-unique wrinkle. ATS's packaging-automation equipment, built in Canadian plants and sold into the US, got caught in Section 38 tariffs that took effect in late August after Canadian-US trade talks broke down. Customer decisions froze mid-quarter. Then, at the end of October — days before this call — the US eliminated the impact on nearly all covered products.

The Section 38 tariffs that came into effect in late August after the breakdown of trade talks between Canada and the United States affected our packaging equipment, and delayed customer decision making in response to the tariffs.
Douglas William Wright, Chief Executive Officer · 2026-11-04

The timing is what makes it interesting. The global thematic machine spent calendar 2025 obsessing over tariff refunds and reciprocal-tariff whiplash — that theme topped the market-wide keyword list back in mid-2025 and was still throwing off top-advancer clusters a quarter later. ATS is a laggard to that story: a $1.7 billion industrial that got hit by a tariff regime roughly a year after the market had already digested, priced, and moved past the headline. And now the resolution lands as a positive catalyst with no corresponding enthusiasm in the market's own theme map. Management refused to size it — “we do not want to give guidance on how quickly that business is going to recover because we literally just got the news a week ago” — Douglas William Wright, Chief Executive Officer · 2026-11-04 — but did concede the packaging business was "pretty material last year." That refusal is why the full-year guide mattered so much. The company had promised "modest" revenue growth and margin expansion for fiscal 2027. In August, Wright insisted “we believe the modest organic revenue growth remains achievable, but it will depend on the timing of larger customer awards” — Douglas Wright, Chief Executive Officer · 2026-08-06. In May, the tone was even breezier — Anne Cybulski framing the moderation as "primarily timing related," and Wright adding that “there's really no real drama in our -- in any of our end markets at this stage” — Douglas Wright, Chief Executive Officer · 2026-05-28. Six months and one tariff order-book freeze later, the guide is gone: “we do not expect to achieve our previous goals for modest revenue growth, and for margin expansion in the year” — Anne Cybulsk, Interim Chief Financial Officer · 2026-11-04. Q3 revenue is being shepherded to $640-680 million, below Q2. That is the tension a reader should hold onto — not the record backlog headline, but the fact that a company spent two quarters calling order timing benign and has now reclassified it as a guidance event.

The cost surgery is real, and genuinely surgical

What deserves credit is the fixed cost transformation program. Announced last quarter as a $65-75 million gross ambition, it was clarified Wednesday as a net number — roughly 250 basis points of margin on a ~10% base, or half of the path to the 15% target. Ten percent of square footage is coming out, largely European overcapacity, with 300-400 people and subcontractors leaving globally. Q2 carried $21.3 million of restructuring charges, about half tied to this program. And the funding is tidy: two former transportation facilities sold for $71.2 million with an estimated $12.2 million gain, one of them leased back to house the growing US nuclear business. Wright was adamant that this is not a universal haircut dressed up as strategy. “Radiopharma, we just completed the expansion of our facility in Bologna. And we just opened up a new... service center in the Central United States, and we just are starting another 1 in Melbourne, Australia.” — Douglas William Wright, Chief Executive Officer · 2026-11-04 Half the savings land in cost of goods, half in SG&A — a useful disclosure, since it tells you the fixed-cost drag is factory absorption, not just headcount. The catch: savings build over 15 months while the margin damage is happening now. Leverage sits at 3.1x net debt to adjusted EBITDA (3.0x excluding $61 million of buybacks), modestly above the 2-3x target range, and management expects to stay "moderately above" for the rest of the fiscal year.

What fell off the page

The most telling keyword move is an absence. Auto injectors — the GLP-1 delivery-machine story that dominated ATS's narrative from fiscal 2023 through mid-2026, landing in the top-10 themes repeatedly — has collapsed in the momentum rankings and dropped out of the company's curated top-30 entirely this quarter. It did not disappear from the call; it was demoted. Cybulski noted a couple more quarters until the GLP-1 comp is lapped, and life sciences revenue ex-GLP-1 actually grew year over year. The growth story has been handed over to med device — diabetes care, vision care, liquid pharma visual inspection, sterilization — plus radiopharma, which is now twice the size of the GLP-1 backlog. That rotation is the most credible thing in the report. Radiopharma and SMR nuclear are genuinely infrastructure-scale opportunities: "whole factories" being built by customers, $100 million-class projects, with the US regulator issuing its first commercial SMR construction permit in Tennessee during the quarter and Darlington advancing in Ontario. It also makes ATS lumpier, and management said so out loud: these are long-cycle, lumpy, first-generation-therapeutic bets. The market's job, implicitly, is to decide whether a 1.05x book-to-bill on a longer-dated backlog is worth the margin air-pocket in the meantime.

The verdict

ATS is not a broken business — it is an impatient one. The order engine is running at a record, the cost program is funded and specific, working capital improved to 13.4% of revenue with $81 million of operating cash flow versus $28 million a year ago, and a discrete regulatory shock has just been lifted off its packaging franchise. But the company has now promised the same thing three times and delivered it zero times, and a shareholder base that watched two quarters of "no drama" language dissolve into a withdrawn guide will price patience accordingly. The next quarter's bookings-to-revenue conversion, not the next booking, is the number that matters.